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Background
In 2008 the Paediatric Rheumathology European Society
(PReS) promoted an International Project for the study
of Autoinflammatory Diseases (AID) named Eurofever
whose main purpose is to create a web-based registry
for the collection of clinical, laboratory and response to
treatment information in patients with AID.
Objectives
To implement the Registry with the new recently
described AID and genes and modify the web-system to
make it suitable for the collection of longitudinal data.
Methods
With the technical help of Paediatric Rheumatology
INternational Trial Organization (PRINTO) web-masters,
we were able to revise the electronic case report forms
bringing 2 main novelties: i) inclusion of the more
recently described AID (DADA2, CAMPS, SAVI) and the
relative clinical manifestation ii) modification of drug lay-
out. In this process information on safety and efficacy
has been included. Very soon Centres will be asked to
update on a yearly base the information regarding each
patient with particular focus on modification of the clini-
cal picture, onset of complication/sequelae, treatment,
adverse events if present, laboratory and instrumental
findings.
Results
At present baseline demographic information from 3089
(M:F=1513:1576) patients from 101 centers in 38 coun-
tries are available. In 77% complete clinical information
from disease onset to diagnosis and response to treat-
ment is also available. For each disease the number of
enrolled patients is: FMF 894 pts (708 with complete
clinical data); TRAPS 268 pts (226 complete); CAPS 284
pts (208 complete); MKD 189 pts (165 complete); Blau’s
disease 71 pts (22 complete); PAPA 27 pts (22 com-
plete); NLRP-12 mediated periodic fever 14 pts (9 com-
plete); DIRA 3 pts (all complete); CANDLE 2 pts (1
complete), Schnitzler 1 pt and Majeed 2 pts (both com-
plete). Among multifactorial autoinflammatory diseases:
PFAPA 612 pts (380 complete); CRMO 417 pts (394
complete); pediatric Bechet disease 92 pts (72 complete)
and 217 patients with undefined periodic fever (182
complete). Longitudinal electronic data capture is now
ready and online for authorized PRINTO members.
Conclusions
A common registry for collection of patients with AID is
available and the enrollment is ongoing. This project
represents the first attempt of a common registry for dif-
ferent autoinflammatory syndromes. The longitudinal col-
lection and analysis of data coming from the Registry will
improve our knowledge in the field of autoinflammation
both on the natural history of the single disease and the
efficacy and safety of the treatment commonly used in the
clinical practice with particular regards to biologics.
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